Related Experiment Videos

[Analysis of FDA medical device recall in 2005-2006]

Qiang Zhang1, Shenglin Liu, Yi Yan

  • 1School of Medicine and Health Management, Tongji Medical College of HUST, Wuhan, 430030, China.

Zhongguo Yi Liao Qi Xie Za Zhi = Chinese Journal of Medical Instrumentation
|November 22, 2011
PubMed
Abstract

Insights

Analysis of FDA medical device recalls reveals significant differences in recall reasons across product classes. Design defects and packaging issues are primary concerns, highlighting areas for improved medical device safety.

Area of Science:

  • Medical Device Safety
  • Regulatory Science
  • Public Health

Context:

  • Medical device recalls are critical indicators of product safety and regulatory oversight.
  • Understanding recall trends is essential for safeguarding patient health.
  • The U.S. Food and Drug Administration (FDA) provides a database of medical device recall information.

Purpose:

  • To analyze FDA U.S. medical device recall data.
  • To identify and categorize the reasons for medical device recalls.
  • To address critical safety issues associated with medical devices.

Summary:

  • A comprehensive analysis of 3093 FDA medical device recall reports was conducted.
  • Key recall reasons identified include packaging problems, design defects, and system failures, varying significantly by product class (materials, tools, equipment).
  • Software recalls accounted for 109 reports, with design defects being the primary cause for high-risk equipment.

Impact:

  • Findings provide crucial insights into the root causes of medical device failures.
  • Recommendations emphasize strengthening the monitoring and application of recall data for regulatory reference.
  • This analysis contributes to a better understanding of medical device safety issues and informs future regulatory strategies.

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Investigation of Disease Outbreaks01:23

Investigation of Disease Outbreaks

Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...